Prediction of treatment outcomes for lamivudine

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 7, 2007, Pages 964-965

  Yuen, Man Fung ^a   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; LAMIVUDINE; TELBIVUDINE;

DRUG APPROVAL; EDITORIAL; GENE MUTATION; GENOTYPE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT OUTCOME; VIREMIA; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 34347385110     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05007.x     Document Type: Editorial

References (16)

1. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998 9 : 61 8.
2. Thompson AJV, Ayres A, Yuen L et al. Lamivudine resistance in patients with chronic hepatitis B: Role of clinical and virological factors. J. Gastroenterol. Hepatol. 2007 22 : 1078 85.
3. Chen RY, Edwards R, Shaw T et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003 37 : 27 35.
4. Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants. J. Virol. 2004 78 : 8524 35.
5. Lok AS, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000 32 : 1145 53.
6. Kuwahara R, Kumashiro R, Murashima S et al. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy. J. Med. Virol. 2004 72 : 26 34.
7. Yuen MF, Sablon E, Libbrecht E et al. Significance of HBV viral load, core promoter/ precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antivir. Ther. 2006 11 : 779 86.
8. Yuen MF, Wong DK, Sablon E et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir. Ther. 2003 8 : 531 4.
9. Westland C, Delaney W 4th, Yang H et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 2003 125 : 107 16.
10. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J. Hepatol. 2000 33 : 998 1002.
11. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology 2002 36 : 1425 30.
12. Erhardt A, Blondin D, Hauck K et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005 54 : 1009 13.
13. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001 34 (4 Part 1 785 91.
14. Locarnini S, Qi X, Arterburn S et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J. Hepatol. 2005 42 (Suppl. 2 17.
15. Lai CL, Leung N, Teo EK et al. Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005 129 : 528 36.
16. Lai CL, Gane E, Liaw YF et al. Maximal early HBV suppression is predictve of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (The Globe Study). Hepatology 2005 42 (Suppl. 1 232A.